Filter by: patients
Home > Community Treatment Reports and Side Effects > pneumococcal polyvalent-23 vaccine Treatment Report
What is pneumococcal polyvalent-23 vaccine?

Pneumococcal polysaccharide vaccine (23-valent) is used with children over 2 years of age and adults who are at increased risk of pneumococcal disease and its complications because of underlying health conditions.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Prevent infection 3 0
Pneumonia symptoms 1 0

See 1 patient currently taking pneumococcal polyvalent-23 vaccine

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 1

Reported Dosages

  one time
  1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking pneumococcal polyvalent-23 vaccine (multiple reasons could be selected)
Reason # Patients Percentage of patients
Not indicated 2   Not indicated: 67%
Course of treatment ended 1   Course of treatment ended: 33%

See all 3 patients who’ve stopped taking pneumococcal polyvalent-23 vaccine

Reported Duration See details about how long patients take this treatment ▼

Currently Taking pneumococcal polyvalent-23 vaccine

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of pneumococcal polyvalent-23 vaccine

Always
 1 100%
Usually
 0 0%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of pneumococcal polyvalent-23 vaccine

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 1 100%

Cost

Paid out of pocket

Cost of pneumococcal polyvalent-23 vaccine

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 26, 2012.